Funder
Innovative Medicines Initiative
Publisher
Springer Science and Business Media LLC
Reference55 articles.
1. Bouvy JC, Cowie L, Lovett R, et al. Use of patient preference studies in HTA decision making: a NICE perspective. Patient. 2020;13(2):145–9.
2. Mott DJ. Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? Patient. 2018;11(3):249–52.
3. Ho M, Saha A, McCleary KK, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. Value Health. 2016;19(6):746–50.
4. Haerry D, Landgraf C, Warner K, et al. EUPATI and patients in medicines research and development: guidance for patient involvement in regulatory processes. Front Med. 2018;5:230.
5. US Food and Drug Administration. Patient preference information: voluntary submission, review in premarket approval applications, humanitarian device exemption applications, and de novo request, and inclusion in decision summaries and device labeling. Guidance for industry. Food and Drug Administration Staff and Other Stakeholders, Center for Devices and Radiological Health and Center for Biologics Evaluation and Research, editors. Silver Spring, MD, 2016.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献